Primary mediastinal B-cell lymphoma
Primary mediastinal B-cell lymphoma
Primary mediastinal B-cell lymphoma (PMBCL) is a sub-type of the heterogeneous diffuse large B-cell lymphoma category, and comprises approximately 5% of all non-Hodgkin's lymphomas (NHL). It was first recognized as a distinct clinico-pathologic entity 20 years ago, and recent work has further characterized specific molecular features. Gene expression profiling has suggested a partial overlap with nodular sclerosing Hodgkin lymphoma (HL), with which it shares some clinical features. The optimal management remains a matter of debate. There is uncertainty as to whether weekly alternating chemotherapy regimens may be more effective than CHOP, whether consolidation radiotherapy (RT) to the mediastinum is always required, whether PET scanning can be used to determine this, and whether the use of rituximab as part of initial therapy will change the answers to these questions. The International Extranodal Lymphoma Study Group (IELSG) 26 clinicopathologic study of PMBCL, which has recently opened, represents a first attempt to gather data prospectively on some of these issues. Copyright (c) 2007 John Wiley & Sons, Ltd
primary mediastinal B-cell lymphoma, immunology, treatment, mediastinum, B-cell lymphoma
157-163
Boleti, E
92179b20-4d83-492a-9801-520cc6944d05
Johnson, PWM
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
18 June 2007
Boleti, E
92179b20-4d83-492a-9801-520cc6944d05
Johnson, PWM
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Boleti, E and Johnson, PWM
(2007)
Primary mediastinal B-cell lymphoma.
Hematological Oncology, 25 (4), .
(doi:10.1002/hon.818).
Abstract
Primary mediastinal B-cell lymphoma (PMBCL) is a sub-type of the heterogeneous diffuse large B-cell lymphoma category, and comprises approximately 5% of all non-Hodgkin's lymphomas (NHL). It was first recognized as a distinct clinico-pathologic entity 20 years ago, and recent work has further characterized specific molecular features. Gene expression profiling has suggested a partial overlap with nodular sclerosing Hodgkin lymphoma (HL), with which it shares some clinical features. The optimal management remains a matter of debate. There is uncertainty as to whether weekly alternating chemotherapy regimens may be more effective than CHOP, whether consolidation radiotherapy (RT) to the mediastinum is always required, whether PET scanning can be used to determine this, and whether the use of rituximab as part of initial therapy will change the answers to these questions. The International Extranodal Lymphoma Study Group (IELSG) 26 clinicopathologic study of PMBCL, which has recently opened, represents a first attempt to gather data prospectively on some of these issues. Copyright (c) 2007 John Wiley & Sons, Ltd
This record has no associated files available for download.
More information
Published date: 18 June 2007
Keywords:
primary mediastinal B-cell lymphoma, immunology, treatment, mediastinum, B-cell lymphoma
Identifiers
Local EPrints ID: 62692
URI: http://eprints.soton.ac.uk/id/eprint/62692
ISSN: 0278-0232
PURE UUID: 6c502632-6472-459c-92d6-5ccf5d48d529
Catalogue record
Date deposited: 10 Sep 2008
Last modified: 16 Mar 2024 02:59
Export record
Altmetrics
Contributors
Author:
E Boleti
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
